Acute graft versus host disease in intestine – Diagnostics – Overview of Information and Clinical Research

Diagnosing acute graft versus host disease in the intestine requires careful evaluation combining clinical observation, endoscopic examination, and tissue analysis, but it can be challenging because symptoms often overlap with infections and other complications after stem cell transplant.

Introduction: Who Should Undergo Diagnostics

Anyone who has received an allogeneic stem cell transplant — a transplant using donor cells — should be carefully monitored for signs of acute graft versus host disease affecting the intestine. This condition occurs when the immune cells from the donated tissue recognize the recipient’s body as foreign and attack healthy tissues, particularly in the gut^[1].

Patients typically need diagnostic evaluation when they develop symptoms like diarrhea, abdominal pain, nausea, vomiting, or loss of appetite, especially within the first 100 days after transplant. However, these symptoms can also appear later^[2]. The gastrointestinal tract is one of the most commonly affected areas, with gut involvement occurring in approximately 60% of patients who develop acute graft versus host disease^[6].

It’s important to seek diagnostic testing promptly because severe manifestations of intestinal acute graft versus host disease carry a poor prognosis. Early and accurate diagnosis allows for timely treatment, which can significantly impact outcomes^[1]. The condition affects around 40% of all patients who undergo allogeneic stem cell transplantation, and gastrointestinal involvement accounts for up to 40% of all acute graft versus host disease cases^[6].

⚠️ Important

Certain factors increase your risk of developing acute intestinal graft versus host disease, including having an unrelated or mismatched donor, receiving a transplant from a female donor, undergoing total body irradiation before transplant, and the intensity of chemotherapy and radiation used in conditioning^[4]. If you have these risk factors, you and your medical team should be especially vigilant about monitoring for symptoms.

Classic Diagnostic Methods

Diagnosing acute graft versus host disease of the intestine presents significant challenges because the clinical symptoms are nonspecific and overlap considerably with those caused by infections and drug toxicity. The diagnosis is ultimately based on clinical criteria, combining multiple pieces of information rather than relying on a single test^[1].

Clinical Assessment

The diagnostic process begins with a thorough clinical evaluation. Doctors assess patient risk factors and carefully review symptoms. The most common symptoms of gastrointestinal acute graft versus host disease include nausea, vomiting, and diarrhea, which can range from mild to severe enough to require hospitalization^[2]. Patients may also experience abdominal cramping, weight loss, and loss of appetite^[4].

The clinical presentation, severity, and prognosis differ depending on which regions of the gastrointestinal tract are involved. The disease is graded from mild (grade 1) to very severe (grade 4), with grade 4 representing the most severe form that causes intense abdominal symptoms, cramping, and pain^[4]. This grading helps doctors determine the appropriate treatment approach.

Endoscopic Examination and Biopsy

Endoscopic examination with biopsy is considered the accepted standard for confirming gastrointestinal acute graft versus host disease. This procedure involves inserting a flexible tube with a camera into the digestive tract to examine the lining and take small tissue samples^[6].

During endoscopy, doctors look for visible changes in the gut lining such as swelling, redness, erosion, ulceration, and sloughing of tissue. However, the mucosa can appear completely normal to the naked eye while still containing microscopic evidence of the disease. For this reason, doctors take biopsies even when the tissue looks healthy^[6].

Under the microscope, the characteristic finding is apoptosis — a type of programmed cell death — of the mucosal epithelial cells that line the digestive tract. In severe cases, the tissue shows sloughing and complete loss of the surface layer^[6]. The extent of this damage visible under the microscope helps confirm the diagnosis.

Despite being the standard diagnostic method, endoscopic biopsy has significant limitations. The tissue samples represent only tiny areas of the intestine, so there’s a risk of missing affected regions — this is called sampling error. Studies have found that up to 26% of patients require treatment for gastrointestinal acute graft versus host disease despite having negative endoscopic biopsies^[6]. Additionally, the biopsy results don’t reliably predict how patients will respond to treatment or what their outcomes will be.

Exclusion of Other Conditions

A critical part of diagnosis involves ruling out other conditions that can cause similar symptoms. Near certainty of diagnosis requires combining a high likelihood of graft versus host disease with negative evidence of infection, consistent physical examination findings, imaging results, endoscopic observations, and typical microscopic changes^[7].

The medical team must exclude infections such as cytomegalovirus (CMV) colitis, bacterial infections, and other viral causes. They also need to consider conditioning-associated mucositis — inflammation caused by the chemotherapy and radiation given before transplant — and drug toxicity^[1]^[6]. This typically involves testing stool specimens and tissue biopsies for infectious organisms.

Imaging Studies

Imaging tests of the gut can provide supportive information, though they cannot definitively diagnose the condition. Doctors use these tests as part of the overall clinical picture to assess the extent and severity of intestinal involvement.

Advanced Imaging with PET Scans

Recent advances have explored the use of positron emission tomography (PET) scanning as a novel diagnostic tool. PET scans use radioactive tracers to create images that show metabolic activity in tissues. This technology offers the potential for non-invasive, real-time assessment of immune activity within the gastrointestinal tract^[6].

PET scanning could potentially identify acute graft versus host disease before symptoms become severe and might help predict which patients will respond to treatment. However, this approach is still being studied and is not yet part of routine clinical practice^[6].

Biomarkers

Researchers have investigated various blood and stool biomarkers that might help diagnose gastrointestinal acute graft versus host disease more easily and accurately. These include certain proteins in the blood and changes in the gut microbiome — the community of bacteria and other organisms living in the intestines^[6].

While promising, reliable serum biomarkers have not yet been validated outside of clinical trials for routine use^[1]. The combination of tissue-based biomarker assessment, including plasma cytokines and analysis of the fecal microbiome, along with molecular imaging, offers potential for future diagnostic strategies^[6].

Some research has shown that patients with a specific species of bacteria called Blautia in their gut have a lower risk of developing acute graft versus host disease, suggesting that microbiome analysis might eventually play a diagnostic or predictive role^[4].

Diagnostics for Clinical Trial Qualification

For patients considering enrollment in clinical trials testing new treatments for acute intestinal graft versus host disease, specific diagnostic criteria must be met. Clinical trials typically require confirmation of the diagnosis through standard methods before patients can participate.

Most clinical trials use the grading system to classify disease severity. Patients are staged from grade 1 through grade 4 based on the volume of diarrhea, presence of abdominal pain, and other symptoms. This staging helps researchers ensure they’re studying similar patient populations and can accurately measure whether experimental treatments are working^[11].

Many trials specifically focus on patients with steroid-resistant disease — meaning their condition hasn’t responded adequately to the standard first-line treatment with corticosteroids. For these studies, patients must have documented evidence that they received appropriate doses of steroids and either didn’t improve or got worse despite this treatment^[8].

Researchers conducting trials often require baseline endoscopic evaluation and biopsy confirmation before enrollment. They may also collect additional tissue samples, blood tests, and stool samples for research purposes, including biomarker studies and microbiome analysis. These research samples help scientists better understand the disease and identify which patients are most likely to benefit from new therapies^[6].

⚠️ Important

Clinical trials testing novel treatments for gastrointestinal acute graft versus host disease often require patients to meet specific eligibility criteria beyond just having the disease. These may include particular levels of organ function, absence of active infections, and willingness to undergo additional monitoring procedures. If you’re interested in participating in a trial, discuss with your transplant team whether you might be eligible and what additional testing might be required.

Some clinical trials are exploring completely new diagnostic approaches. For example, recent studies have tested whether measurements like albumin levels — a protein in the blood that reflects nutritional status — can help predict treatment response. Researchers have observed that many patients experience an increase in albumin levels within two months after starting certain treatments, even if their clinical symptoms don’t immediately improve^[9].

Advanced imaging studies are also being incorporated into some clinical trials. Researchers are evaluating whether PET scans performed before and after treatment can accurately measure disease activity and predict which patients will respond to therapy. This information could help tailor treatments to individual patients in the future^[6].

The field is rapidly evolving, with new understanding of how the disease develops at the molecular level. Scientists have discovered that acute graft versus host disease causes loss of specialized cells in the intestine called neuroendocrine L-cells, leading to reduced levels of a hormone called glucagon-like peptide-2. This discovery has led to clinical trials testing whether replacing this hormone might help treat the condition^[9].

For clinical trial participation, patients should understand that research studies may involve more frequent blood draws, imaging tests, endoscopies, and clinic visits compared to standard care. However, participation in trials gives patients access to potentially beneficial new treatments before they become widely available and contributes to advancing medical knowledge that will help future patients.

Prognosis and Survival Rate

Prognosis

The prognosis for patients with acute graft versus host disease of the intestine depends heavily on the severity of the condition and how well it responds to treatment. Severe manifestations of gastrointestinal acute graft versus host disease carry a particularly poor prognosis^[1]. Over the past two decades, the incidence of severe acute graft versus host disease has declined substantially, which represents important progress. This decline is significant because historically, patients with severe acute graft versus host disease have had very limited chances of recovery^[4].

The clinical presentation and severity differ depending on which regions of the gastrointestinal tract are involved, with this affecting both prognosis and treatment outcomes^[6]. Prolonged exposure to immunosuppressive therapies needed to control the disease, failure to achieve tolerance where the donor and recipient cells coexist peacefully, and inadequate responses to treatment are the main causes of deaths related to graft versus host disease^[7].

Patients with gastrointestinal acute graft versus host disease face increased risk of serious complications including severe hemorrhage (bleeding), perforation of the intestine, and secondary infections. These complications can be life-threatening^[6]. The disease also frequently causes severe malnutrition and profuse diarrhea, which become critical management issues requiring specialized supportive care^[1].

Approximately 35 to 60% of patients with acute graft versus host disease achieve a durable response to the first-line treatment with corticosteroids. However, patients who do not achieve an adequate response to initial steroid therapy face an increased risk of death^[8]. For those with steroid-resistant disease, especially severe intestinal forms, prognosis remains challenging and represents an unmet medical need^[8].

Survival rate

The survival rates for acute gastrointestinal graft versus host disease vary considerably based on severity. Historical data shows that only 5 to 20% of patients with severe acute graft versus host disease survived^[4]. This sobering statistic underscores why early detection and aggressive treatment are so critical.

Among all patients who develop acute graft versus host disease, approximately 30 to 50% will be affected. Most cases are mild, but roughly 10% of patients experience more severe symptoms that carry higher mortality risk^[4]. The gastrointestinal tract is involved in a substantial proportion of cases, with gut involvement occurring in about 40% of acute graft versus host disease patients^[6].

Recent advances in prevention, diagnosis, and treatment have improved outcomes. The development of new therapeutic agents and better supportive care strategies means that current survival rates are improving compared to historical data. However, intestinal acute graft versus host disease still significantly contributes to post-transplant mortality and morbidity^[9].

Deaths from graft versus host disease remain a continuing obstacle to successful transplantation, even though the condition is essentially an iatrogenic illness — one caused by medical treatment^[7]. Apart from the risk of the original disease coming back, acute graft versus host disease remains a major cause of death after allogeneic stem cell transplantation^[9].

#1 Clinical Trials Search in Europe